Vimarsana
Biggest News Aggregation in the World

Page 14 - Specific Populations News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Specific Populations. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Specific Populations Today - Breaking & Trending Today

Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® Plus LENVIMA® in Two Different Types of Cancer - Vimarsana News

Merck and Eisai Receive Positive EU CHMP Opinions for KEYTRUDA® Plus LENVIMA® in Two Different Types of Cancer

Positive Opinion Granted for Advanced Renal Cell Carcinoma Based on Significant Progression-Free Survival Overall Survival and Objective Response Rate Benefit Compared to Sunitinib in CLEARKEYNOTE-581 Trial Positive Opinion Granted for Advanced Endometrial Carcinoma Based on Significant OS and PFS Benefit Compared to Chemotherapy in KEYNOTE-775Study 309 Trial Merck known as MSD outside the United States and Canada, ...

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19 - Vimarsana News

FDA Accepts REGEN-COV® (casirivimab and imdevimab) for Priority Review for Treatment and Prophylaxis of COVID-19

/PRNewswire/ -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that the U.S. Food and Drug Administration (FDA) has accepted for priority...

New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19 - Vimarsana News

New REGEN-COV™ (casirivimab and imdevimab) Data Show Supportive Results in Patients Hospitalized with COVID-19

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection - Vimarsana News

UK Authorizes Regeneron Antibody Cocktail to Prevent and Treat Acute COVID-19 Infection

Press release content from PR Newswire. The AP news staff was not involved in its creation.

Source: apnews.com
FDA Approves KEYTRUDA® Plus LENVIMA® Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma - Vimarsana News

FDA Approves KEYTRUDA® Plus LENVIMA® Combination for First-Line Treatment of Adult Patients With Advanced Renal Cell Carcinoma

KEYTRUDA Plus LENVIMA Is Now Approved for Two Types of Cancer, Including Advanced RCC Based on Phase 3 CLEARKEYNOTE-581 Trial, KEYTRUDA Plus LENVIMA Significantly Reduced Risk of Disease Progression or Death by 61% Versus Sunitinib Merck known as MSD outside the United States and Canada, and Eisai today announced that the U.S. Food and Drug Administration has approved the combination of KEYTRUDA, Merck’s anti-PD-1 ...